Merrill S. Goldenberg, Ph.D.
Dr. Goldenberg has 40 years of experience in the biopharma/biotech industry in designing polymeric drug delivery/sustained release systems involving proteins, peptides, and small molecules. He is also an expert in high concentration proteins, viscosity/rheology, biomedical polymers, subcutaneous injection (force, etc.), and AAV characterization. Since 2015, he has been the President of GoldenBiotech, LLC. in Thousand Oaks, CA, which has a fully equipped biopharma and organic/polymer lab. He performs contract feasibility studies. Current programs include formulation and characterization of AAVs (Adeno-Associated Viruses) and nonviral vectors, including their transduction efficiency into mammalian cells, near zero order multi-month ocular delivery of prostaglandin analogues to treat glaucoma, novel antiviral formulations to treat seriously ill COVID-19 patients, and “tailor made” sustained release systems. He was with Amgen for over 22 years, with his last position as Scientific Director in the Formulation and Analytical Research/Process and Product Development Department. His group’s efforts led to one of Amgen’s key products—a pegylated protein, Neulasta. Prior to Amgen, he was with Novartis (formerly Ciba-Geigy) for 11 years, with his last position as Research Fellow in the Chemicals Division and Central Research Department. His efforts there led to a marketed hydrogel contact lens — Excelens. He has numerous publications and patents. He did postdoctoral work at Columbia University in organic and biophysical chemistry and holds a Ph.D. in Organic and Polymer Chemistry from New York University Tandon School of Engineering (formerly Polytechnic Institute of New York).